This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Multiple sclerosis (MS)	BET bromodomain proteins	<p><i>In vitro</i> and cell culture studies suggest selective inhibitors of BET bromodomain proteins could be useful for promoting myelin regeneration in MS. BET bromodomain proteins contain two bromodomains, BRD1 and BRD2. <i>In vitro</i> structure-guided design studies identified a class of compounds selective for BRD1 over BRD2. In a cell culture assay of oligodendrocyte maturation, the best BRD1-selective compound increased differentiation and myelin production compared with nonselective inhibitors that target BRD1 and BRD2. Next steps include evaluating the compounds in rodent models of remyelination.</p> <p>Biogen Idec Inc.'s BIIB033, a mAb that promotes remyelination, is in Phase II testing in MS.</p> <p>Inception 5 Inc. has preclinical compounds to promote oligodendrocyte maturation in development for MS.</p> <p>SciBX 7(29); doi:10.1038/scibx.2014.852 Published online July 31, 2014</p>	Patent pending; available for licensing	<p>Gacias, M. <i>et al. Chem. Biol.</i>; published online June 17, 2014; doi:10.1016/j.chembiol.2014.05.009 Contact: Ming-Ming Zhou, Icahn School of Medicine at Mount Sinai, New York, N.Y. e-mail: ming-ming.zhou@mssm.edu Contact: Patrizia Casaccia, same affiliation as above e-mail: patrizia.casaccia@mssm.edu</p>